Raptor Pharmaceutical to Participate in the Leerink Partners 5th Global Healthcare Conference
February 08, 2016 07:30 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Feb. 08, 2016 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that it will participate in the following investor conference: Julie Anne Smith,...
Four New Patents Issued, PROCYSBI® Granted Additional U.S. Orphan Exclusivity
January 25, 2016 07:05 ET
|
Raptor Pharmaceutical Inc
Five Patents for PROCYSBI Now Listed in FDA Orange Book Orphan Drug Exclusivity Extended in Nephropathic Cystinosis Patients 2-6 Years Old NOVATO, Calif., Jan. 25, 2016 (GLOBE NEWSWIRE) -- Raptor...
NIDDK Provides Additional Data From CyNCh Study Evaluating RP103 in Pediatric NASH at AASLD
November 16, 2015 07:05 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Nov. 16, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (NASDAQ:RPTP) today announced researchers have provided additional results from the CyNCh study of RP103 for the treatment...
Raptor Pharmaceutical Corp. Reports Third Quarter 2015 Financial Results and Provides Corporate Update
November 05, 2015 16:04 ET
|
Raptor Pharmaceutical Inc
Record PROCYSBI® Product Sales of $25.8 Million
Raptor Raises 2015 PROCYSBI Revenue Guidance to $90-$95 Million
Company to Host Conference Call and Webcast Today at 4:30 p.m. EST
NOVATO,...
Raptor Pharmaceutical to Hold Third Quarter 2015 Financial Results Conference Call and Webcast on Thursday, November 5, 2015, at 4:30 p.m. ET
October 29, 2015 16:05 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Oct. 29, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that the company will release third quarter 2015 financial results on Thursday, November 5,...
Raptor Pharmaceutical Provides Topline Results From Phase 2b CyNCh Study Evaluating RP103 in Pediatric Nonalcoholic Steatohepatitis
September 14, 2015 07:05 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Sept. 14, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced topline results from the Phase 2b CyNCh study, which did not meet its primary endpoint of...
Raptor Pharmaceutical Corp. Expands Rare Disease Portfolio With the Acquisition of Quinsair(TM)
August 20, 2015 17:16 ET
|
Raptor Pharmaceutical Inc
First Inhaled Fluoroquinolone Therapy for Patients with Cystic Fibrosis
Approval Received in the European Union and Canada
Expansion of Pipeline with Multiple Late-Stage Orphan Indication...
Raptor Pharmaceutical Voted a "Best Places to Work" Company in the North San Francisco Bay Area
August 20, 2015 14:46 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Aug. 20, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) announced today that it was named among the top workplaces in the North Bay in the 10th Annual North Bay...
Raptor Pharmaceutical Receives FDA Approval of Expanded Label for PROCYSBI(R) to Treat Children Aged 2-6 Years With Nephropathic Cystinosis
August 17, 2015 07:05 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Aug. 17, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (NASDAQ:RPTP) today announced that the U.S. Food and Drug Administration (FDA) approved the expanded use of PROCYSBI®...
Raptor Pharmaceutical Corp. Reports Second Quarter 2015 Financial Results and Provides Corporate Update
August 06, 2015 16:04 ET
|
Raptor Pharmaceutical Inc
PROCYSBI® Product Sales Increased 43% Year over Year to $23.3 Million in Second Quarter
Balance Sheet Strengthened with over $220 Million in Cash, Cash Equivalents and Short-Term Investments...